[Form 4] DAKTRONICS INC /SD/ Insider Trading Activity
DAKT Form 4: Director Lance D. Bultena reported an acquisition of 3,535 shares of Daktronics Inc. common stock on 09/15/2025 at a reported price of $24.04 per share. After this transaction he beneficially owns 47,040 shares. The reported shares are restricted stock that vests one year from the grant date, per the form's explanation. The filing identifies Mr. Bultena as a director and was signed on 09/16/2025.
- Director equity alignment: 3,535 restricted shares vesting in one year align the director's interests with shareholders
- Transparent disclosure: Form 4 reports transaction date, price ($24.04), and resulting beneficial ownership (47,040 shares)
- Potential dilution: The grant increases outstanding director-held shares by 3,535, though the form does not state total shares outstanding to assess magnitude
- No vesting schedule detail beyond one year: Form notes one-year vesting but provides no additional terms (e.g., forfeiture conditions) in this filing
Insights
TL;DR: Director received a time‑vested restricted stock grant of 3,535 shares, aligning interests with shareholders without immediate sale.
The Form 4 discloses a routine director equity grant that vests one year from grant date. Such restricted awards are commonly used to retain directors and align their incentives with long‑term shareholder value. The transaction increased the director's beneficial ownership to 47,040 shares and was executed at $24.04 per share. There is no indication of derivative transactions or immediate disposition. From a governance perspective, the disclosure is standard and transparent.
TL;DR: The filing shows a straightforward equity grant; impact on share count and immediate dilution is limited to the granted amount.
The reported acquisition of 3,535 restricted shares represents a definable increase in the director's stake. The Form 4 lists the acquisition code as A and the shares are restricted with vesting one year later, implying no immediate market sale. The price reported ($24.04) documents the grant valuation for disclosure; the form does not provide companywide share count, so percent dilution cannot be calculated from this filing alone.